drugset / Trial / NCT06648525
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma (ICC).
Timeline
- Start
- 2024-10
- Primary completion
- 2027-04
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Subject | Calcium folinate | Unknown | — | Intravenous |
| Subject | Irinotecan liposomes | Unknown | — | Intravenous |
| Subject | Lenvatinib | Small molecule | — | Oral |
| Subject | fluorouracil | Small molecule | — | Intravenous |